An underground market for unlicensed weight-loss medications is propelled by social media fitness personalities and sellers on messaging platforms, according to new investigations.
Investigational Treatment Gaining Popularity Via Social Media
The experimental drug, which is still in research studies, is being advertised by online personalities for its alleged fat-burning properties. Followers are encouraged to message these accounts privately for source information, while also receiving promotional offers.
Active Trade on Social Networks
Separately, a flourishing trade exists on Telegram, where communities with thousands of participants share “before and after” photos, administration instructions and assertions of next-day UK delivery. Vendors market the substance there before directing buyers to other platforms for purchases.
Understanding The Experimental Drug
This medication is an investigational injectable developed by US drugmaker Eli Lilly. The drug affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist individuals lose up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted online as the successor to Ozempic.
Medical Experts Express Worries
However, physicians and pharmacists have cautions that the distribution of what is still an unapproved medication in the United Kingdom is a cause for concern and could lead to individuals injecting products of unknown origin.
Some experts said the popularity for the experimental drug could be connected to the increasing cost of approved weight loss treatments such as Mounjaro.
Legal Position and Enforcement
Marketing the unapproved drug on TikTok or messaging apps is prohibited in the UK, as it is an unlicensed drug that must not be promoted or distributed for human use under the Human Medicines Regulations 2012.
Some content creators attempt to circumvent the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but advertising and distribution can still breach medicines, marketing, and consumer regulations, risking fines, prosecution or imprisonment.
Platform Response and Material Removal
According to the social media company, the platform has removed violative content and banned associated keywords and search suggestions. The company stated it was committed to keeping the platform secure and investing in enhancing compliance measures.
Digital Marketplace Operations
Investigations also discovered communities with up to nine thousand members marketing the experimental drug using Telegram's integrated search feature, which operates like a public directory. Entering “retatrutide” immediately brings up channels with thousands of users, populated with photos of weight loss, glowing testimonials and detailed instructions for preparing or injecting at residence.
After moments of entering one community, a vendor shared contact information, where most transactions take place. The seller sent an instruction manual and promised shipping within 48 hours. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one asked about body mass, medical conditions or past usage.
Product Details and Pricing
Within these communities, messages display black plastic packages with postal service stickers, stating to include new batches. One message read: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at residence with purified liquid, or pre-filled injectors usually sold at £160 for 20 milligrams. When asked how long a injector should be used, vendors give contradictory responses varying between a several days to “depends on your body”.
Platform Moderation and Security Actions
A representative for the messaging service said it regularly monitored dangerous content on its platform including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Medical Expert Warnings
“People are injecting substances they can’t verify. Although the science behind this drug is valid, these online products may not contain what they advertise,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor connected the surge in interest to recent price rises for approved slimming medications such as Mounjaro. “With costs increasing, patients are using social media. But fake treatments are extremely risky. You cannot know what’s contained or whether the conditions they were made in was clean,” she said.
Her staff has previously seen patients harmed by personal administration from unconfirmed sources. “We understand the disappointment, but buying from messaging apps or WhatsApp is gambling with your well-being,” stated the doctor. “These substances could be impure or improperly measured.”
Producer Position
A spokesperson from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can market [it] for human use,” they said, noting that any product “misleadingly claiming itself as a company investigational substance not yet approved … may subject users to possibly significant health risks”.
